Novel coronavirus – SARS CoV-2
Abstract Coronaviruses cause a variety of diseases in mammals and birds. In late December, 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV). This virus appears to be a new human pathogen. In this article the biology of virus has been described, replication cycle and epidemiology of COVID 19. The next part discusses current methods of laboratory diagnostics. The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2. Researchers are therefore focusing on steps in the CoV replication cycle that may be target to inhibition by broad-spectrum or specific antiviral agents. Many laboratories focus on vaccine development. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality if the virus establishes itself in the human population..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Zdrowie publiczne - 129(2019), 4 vom: 01. Dez., Seite 113-117 |
| Beteiligte Personen: |
Polz-Dacewicz, Małgorzata [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© 2020 Małgorzata Polz-Dacewicz, published by Sciendo |
|---|
| doi: |
10.2478/pjph-2019-0026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2142193005 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2142193005 | ||
| 003 | DE-627 | ||
| 005 | 20230811134830.0 | ||
| 007 | tu | ||
| 008 | 230811s2019 xx ||||| 00| ||und c | ||
| 024 | 7 | |a 10.2478/pjph-2019-0026 |2 doi | |
| 035 | |a (DE-627)OLC2142193005 | ||
| 035 | |a (DE-B1597)pjph-2019-0026-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Polz-Dacewicz, Małgorzata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel coronavirus – SARS CoV-2 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © 2020 Małgorzata Polz-Dacewicz, published by Sciendo | ||
| 520 | |a Abstract Coronaviruses cause a variety of diseases in mammals and birds. In late December, 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV). This virus appears to be a new human pathogen. In this article the biology of virus has been described, replication cycle and epidemiology of COVID 19. The next part discusses current methods of laboratory diagnostics. The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2. Researchers are therefore focusing on steps in the CoV replication cycle that may be target to inhibition by broad-spectrum or specific antiviral agents. Many laboratories focus on vaccine development. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality if the virus establishes itself in the human population. | ||
| 773 | 0 | 8 | |i Enthalten in |t Zdrowie publiczne |d Sciendo, 1934 |g 129(2019), 4 vom: 01. Dez., Seite 113-117 |w (DE-627)167904558 |w (DE-600)603441-X |w (DE-576)9167904556 |x 0044-2011 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2019 |g number:4 |g day:01 |g month:12 |g pages:113-117 |
| 856 | 4 | 1 | |u https://doi.org/10.2478/pjph-2019-0026 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2019 |e 4 |b 01 |c 12 |h 113-117 | ||